{
    "xml": "<topic id=\"PHP3699\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/fluconazole\" basename=\"fluconazole\" title=\"FLUCONAZOLE\">\n<title>FLUCONAZOLE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_301\" namespace=\"/interactions/list-of-drug-interactions/antifungals/antifungals-triazole/fluconazole\">Fluconazole</xref>\n</p>\n<data name=\"vtmid\">31865003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_107866011\" title=\"Triazole antifungals\">Triazole antifungals</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP47884\" outputclass=\"indicationsAndDose\" rev=\"1.53\" parent=\"/drugs/fluconazole\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Candidal balanitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>150&#8239;mg for 1 dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg for 1 dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Vaginal candidiasis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>150&#8239;mg for 1 dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg for 1 dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Vulvovaginal candidiasis (recurrent)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 150&#8239;mg every 72&#8239;hours for 3 doses, then 150&#8239;mg once weekly for 6 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mucosal candidiasis (except genital)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years</p>\n<p>3&#8211;6&#8239;mg/kg, dose to be given on first day, then 3&#8239;mg/kg daily (max. per dose 100&#8239;mg) for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>50&#8239;mg for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100&#8239;mg daily, increased dose only for unusually difficult infections.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg daily given for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections; increased to 100&#8239;mg daily, increased dose only for unusually difficult infections.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Tinea pedis, corporis, cruris, pityriasis versicolor</p>\n<p outputclass=\"therapeuticIndication\">Dermal candidiasis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg daily for 2&#8211;4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>6&#8211;12&#8239;mg/kg daily (max. per dose 800&#8239;mg) treatment continued according to response (at least 8 weeks for cryptococcal meningitis).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg, dose to be given on first day, then 200&#8211;400&#8239;mg daily (max. per dose 800&#8239;mg daily) treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of fungal infections in immunocompromised patients</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>3&#8211;12&#8239;mg/kg daily (max. per dose 400&#8239;mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8211;400&#8239;mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>400&#8239;mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>200&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47758\" outputclass=\"unlicensedUse\" rev=\"1.9\" parent=\"/drugs/fluconazole\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Not licensed for tinea infections in children, or for vaginal candidiasis in girls under 16 years, or for prevention of relapse of cryptococcal meningitis after completion of primary therapy in children with AIDS.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48017\" outputclass=\"contraindications\" rev=\"1.18\" parent=\"/drugs/fluconazole\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP48032\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/fluconazole\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Susceptibility to QT interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47871\" outputclass=\"interactions\" rev=\"1.16\" parent=\"/drugs/fluconazole\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antifungals, triazole); in general, fluconazole interactions in Appendix 1 relate to multiple-dose treatment.</p>\n<p>Caution with concomitant use of hepatotoxic drugs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47784\" outputclass=\"sideEffects\" rev=\"1.28\" parent=\"/drugs/fluconazole\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal discomfort</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">anaphylaxis</ph>; <ph outputclass=\"sideEffect\">angioedema</ph> (in children); <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">hepatic disorders</ph>; <ph outputclass=\"sideEffect\">hyperlipidaemia</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph> (in adults); <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">seizures</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypokalaemia</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47853\" outputclass=\"pregnancy\" parent=\"/drugs/fluconazole\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;multiple congenital abnormalities reported with long-term high doses.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48040\" outputclass=\"breastFeeding\" parent=\"/drugs/fluconazole\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk but amount probably too small to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47966\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fluconazole\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Toxicity with related drugs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47810\" outputclass=\"renalImpairment\" parent=\"/drugs/fluconazole\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Usual initial dose then halve subsequent doses if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Usual initial dose then halve subsequent doses if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> .</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47747\" outputclass=\"monitoringRequirements\" parent=\"/drugs/fluconazole\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function with high doses or extended courses&#8212;discontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48060\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/fluconazole\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>intravenous infusion</i>, give over 10&#8211;30 minutes; do not exceed an infusion rate of 5&#8211;10&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58492\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/fluconazole\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include orange.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47706\" outputclass=\"professionSpecificInformation\" rev=\"1.14\" parent=\"/drugs/fluconazole\">\n<title>Profession specific information</title>\n<body>\n<section outputclass=\"dentalPractitionersFormulary\">\n<title>Dental practitioners' formulary</title>\n<sectiondiv>\n<p>Fluconazole Capsules 50&#8239;mg may be prescribed.</p>\n<p>Fluconazole Oral Suspension 50&#8239;mg/5&#8239;mL may be prescribed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47693\" outputclass=\"exceptionsToLegalCategory\" rev=\"1.15\" parent=\"/drugs/fluconazole\">\n<title>Exceptions to legal category</title>\n<body>\n<section>\n<sectiondiv>\n<p>Fluconazole capsules can be sold to the public for vaginal candidiasis and associated candidal balanitis in those aged 16&#8211;60 years, in a container or packaging containing not more than 150&#8239;mg and labelled to show a max. dose of 150&#8239;mg.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3699-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fluconazole\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74600\" title=\"Capsule\" namespace=\"/drugs/fluconazole/capsule\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74594\" title=\"Oral suspension\" namespace=\"/drugs/fluconazole/oral-suspension\">Oral suspension</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101318\" title=\"Infusion\" namespace=\"/drugs/fluconazole/infusion\">Infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74617\" title=\"Solution for infusion\" namespace=\"/drugs/fluconazole/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78234\" namespace=\"/treatment-summaries/antifungals-systemic-use\" title=\"Antifungals, systemic use\" count=\"16\" rel=\"backlink\">Antifungals, systemic use</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78284\" namespace=\"/treatment-summaries/skin-infections\" title=\"Skin infections\" count=\"1\" rel=\"backlink\">Skin infections</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78408\" namespace=\"/treatment-summaries/oropharyx-infections-fungal\" title=\"Oropharyx infections, fungal\" count=\"4\" rel=\"backlink\">Oropharyx infections, fungal</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78412\" namespace=\"/treatment-summaries/vaginal-and-vulval-conditions\" title=\"Vaginal and vulval conditions\" count=\"1\" rel=\"backlink\">Vaginal and vulval conditions</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_301\" namespace=\"/interactions/list-of-drug-interactions/antifungals/antifungals-triazole/fluconazole\" title=\"Fluconazole\" count=\"1\" rel=\"link\">Fluconazole</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74600\" namespace=\"/drugs/fluconazole/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74594\" namespace=\"/drugs/fluconazole/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101318\" namespace=\"/drugs/fluconazole/infusion\" title=\"Infusion\" count=\"1\" rel=\"link\">Infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74617\" namespace=\"/drugs/fluconazole/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP3699",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/fluconazole",
    "basename": "fluconazole",
    "title": "FLUCONAZOLE",
    "interactants": [
        {
            "id": "bnf_int_301",
            "label": "Fluconazole"
        }
    ],
    "vtmid": "31865003",
    "drugClassification": [
        "Triazole antifungals"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Candidal balanitis",
                        "html": "Candidal balanitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg for 1 dose.",
                        "html": "<p>150&#8239;mg for 1 dose.</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg for 1 dose.",
                        "html": "<p>150&#8239;mg for 1 dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Vaginal candidiasis",
                        "html": "Vaginal candidiasis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg for 1 dose.",
                        "html": "<p>150&#8239;mg for 1 dose.</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg for 1 dose.",
                        "html": "<p>150&#8239;mg for 1 dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Vulvovaginal candidiasis (recurrent)",
                        "html": "Vulvovaginal candidiasis (recurrent)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 150 mg every 72 hours for 3 doses, then 150 mg once weekly for 6 months.",
                        "html": "<p>Initially 150&#8239;mg every 72&#8239;hours for 3 doses, then 150&#8239;mg once weekly for 6 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mucosal candidiasis (except genital)",
                        "html": "Mucosal candidiasis (except genital)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "3&#8211;6 mg/kg, dose to be given on first day, then 3 mg/kg daily (max. per dose 100 mg) for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections).",
                        "html": "<p>3&#8211;6&#8239;mg/kg, dose to be given on first day, then 3&#8239;mg/kg daily (max. per dose 100&#8239;mg) for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections).</p>",
                        "ageGroup": "1 month&#8211;11 years"
                    },
                    {
                        "textContent": "50 mg for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections.",
                        "html": "<p>50&#8239;mg for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100&#8239;mg daily, increased dose only for unusually difficult infections.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "50 mg daily given for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections; increased to 100 mg daily, increased dose only for unusually difficult infections.",
                        "html": "<p>50&#8239;mg daily given for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections; increased to 100&#8239;mg daily, increased dose only for unusually difficult infections.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Tinea pedis, corporis, cruris, pityriasis versicolor",
                        "html": "Tinea pedis, corporis, cruris, pityriasis versicolor"
                    },
                    {
                        "textContent": "Dermal candidiasis",
                        "html": "Dermal candidiasis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "50 mg daily for 2&#8211;4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks.",
                        "html": "<p>50&#8239;mg daily for 2&#8211;4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)",
                        "html": "Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous infusion",
                    "html": "By mouth or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "6&#8211;12 mg/kg daily (max. per dose 800 mg) treatment continued according to response (at least 8 weeks for cryptococcal meningitis).",
                        "html": "<p>6&#8211;12&#8239;mg/kg daily (max. per dose 800&#8239;mg) treatment continued according to response (at least 8 weeks for cryptococcal meningitis).</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "400 mg, dose to be given on first day, then 200&#8211;400 mg daily (max. per dose 800 mg daily) treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections.",
                        "html": "<p>400&#8239;mg, dose to be given on first day, then 200&#8211;400&#8239;mg daily (max. per dose 800&#8239;mg daily) treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of fungal infections in immunocompromised patients",
                        "html": "Prevention of fungal infections in immunocompromised patients"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous infusion",
                    "html": "By mouth or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "3&#8211;12 mg/kg daily (max. per dose 400 mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia.",
                        "html": "<p>3&#8211;12&#8239;mg/kg daily (max. per dose 400&#8239;mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia.</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "50&#8211;400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk.",
                        "html": "<p>50&#8211;400&#8239;mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)",
                        "html": "Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous infusion",
                    "html": "By mouth or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range.",
                        "html": "<p>400&#8239;mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy",
                        "html": "Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous infusion",
                    "html": "By mouth or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "200 mg daily.",
                        "html": "<p>200&#8239;mg daily.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Not licensed for tinea infections in children, or for vaginal candidiasis in girls under 16 years, or for prevention of relapse of cryptococcal meningitis after completion of primary therapy in children with AIDS.",
                "html": "<p>Not licensed for tinea infections in children, or for vaginal candidiasis in girls under 16 years, or for prevention of relapse of cryptococcal meningitis after completion of primary therapy in children with AIDS.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Susceptibility to QT interval prolongation",
                "html": "Susceptibility to QT interval prolongation"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antifungals, triazole); in general, fluconazole interactions in Appendix 1 relate to multiple-dose treatment.\n\nCaution with concomitant use of hepatotoxic drugs.",
                "html": "<p>Appendix 1 (antifungals, triazole); in general, fluconazole interactions in Appendix 1 relate to multiple-dose treatment.</p><p>Caution with concomitant use of hepatotoxic drugs.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal discomfort",
                        "html": "Abdominal discomfort",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "anaphylaxis",
                        "html": "anaphylaxis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "angioedema in children",
                        "html": "angioedema in children",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon",
                            "patientType": "children"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hepatic disorders",
                        "html": "hepatic disorders",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyperlipidaemia",
                        "html": "hyperlipidaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypersensitivity reactions in adults",
                        "html": "hypersensitivity reactions in adults",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "seizures",
                        "html": "seizures",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hypokalaemia",
                        "html": "Hypokalaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS.",
                "html": "<p>If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;multiple congenital abnormalities reported with long-term high doses.",
                "html": "<p>Manufacturer advises avoid&#8212;multiple congenital abnormalities reported with long-term high doses.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk but amount probably too small to be harmful.",
                "html": "<p>Present in milk but amount probably too small to be harmful.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Toxicity with related drugs.",
                "html": "<p>Toxicity with related drugs.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Usual initial dose then halve subsequent doses if eGFR less than 50 mL/minute/1.73 m2.",
                "html": "<p>Usual initial dose then halve subsequent doses if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Usual initial dose then halve subsequent doses if estimated glomerular filtration rate less than 50 mL/minute/1.73 m2 .",
                "html": "<p>Usual initial dose then halve subsequent doses if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> .</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function with high doses or extended courses&#8212;discontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis).",
                "html": "<p>Monitor liver function with high doses or extended courses&#8212;discontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, give over 10&#8211;30 minutes; do not exceed an infusion rate of 5&#8211;10 mL/minute.",
                "html": "<p>For <i>intravenous infusion</i>, give over 10&#8211;30 minutes; do not exceed an infusion rate of 5&#8211;10&#8239;mL/minute.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include orange.",
                "html": "<p>Flavours of oral liquid formulations may include orange.</p>"
            }
        ]
    },
    "professionSpecificInformation": {
        "dentalPractitionersFormulary": [
            {
                "type": "dentalPractitionersFormulary",
                "textContent": "Fluconazole Capsules 50 mg may be prescribed.\n\nFluconazole Oral Suspension 50 mg/5 mL may be prescribed.",
                "html": "<p>Fluconazole Capsules 50&#8239;mg may be prescribed.</p><p>Fluconazole Oral Suspension 50&#8239;mg/5&#8239;mL may be prescribed.</p>"
            }
        ]
    },
    "exceptionsToLegalCategory": {
        "exceptionsToLegalCategory": [
            {
                "type": "exceptionsToLegalCategory",
                "textContent": "Fluconazole capsules can be sold to the public for vaginal candidiasis and associated candidal balanitis in those aged 16&#8211;60 years, in a container or packaging containing not more than 150 mg and labelled to show a max. dose of 150 mg.",
                "html": "<p>Fluconazole capsules can be sold to the public for vaginal candidiasis and associated candidal balanitis in those aged 16&#8211;60 years, in a container or packaging containing not more than 150&#8239;mg and labelled to show a max. dose of 150&#8239;mg.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74600",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74594",
                "label": "Oral suspension",
                "type": "medicinalForm"
            },
            {
                "id": "PHP101318",
                "label": "Infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74617",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78234",
                "label": "Antifungals, systemic use",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78284",
                "label": "Skin infections",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78408",
                "label": "Oropharyx infections, fungal",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78412",
                "label": "Vaginal and vulval conditions",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_301",
                "label": "Fluconazole",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74600",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74594",
                "label": "Oral suspension",
                "type": "medicinalForm"
            },
            {
                "id": "PHP101318",
                "label": "Infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74617",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}